>
Viralytics logo

VLA - Viralytics Share Price

A$1.75 0.0  0.0%

Last Trade - 05/06/18

Sector
Healthcare
Size
Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £6.21m
Position in Universe th / 1911
Bullish
Bearish
Unlock VLA Revenue
Momentum
Relative Strength (%)
1m +1.47%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2012 2013 2014 2015 2016 2017 2018E 2019E CAGR / Avg
1.20 2.76 2.80 2.98 5.17 7.02 5.90 6.10 +42.4%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 31 December 2017,Viralytics Ltd. revenues increased from A$380K to A$5.3M.Net loss increased 30% to A$9.3M. Revenues reflect R&D TaxIncentive increase from A$94K to A$5.1M. Higher net lossreflects Drug product increase from A$715K to A$4.1M(expense), Clinical trials increase of 51% to A$5.7M(expense), Unrealised foreign exchange gain decrease fromA$682K (income) to A$0K.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

VLA Revenue Unlock VLA Revenue

Net Income

VLA Net Income Unlock VLA Revenue

Normalised EPS

VLA Normalised EPS Unlock VLA Revenue

PE Ratio Range

VLA PE Ratio Range Unlock VLA Revenue

Dividend Yield Range

VLA Dividend Yield Range Unlock VLA Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
VLA EPS Forecasts Unlock VLA Revenue
Profile Summary

Viralytics Limited is a biotechnology company. The Company focuses on the development and commercialization of oncolytic immunotherapies that harness the power of certain viruses to preferentially infect and kill cancer cells. The principal activity of the Company is clinical and preclinical development of its lead product, CAVATAK. CAVATAK is a formulation of the common cold Coxsackievirus Type A21. CAVATAK binds to specific receptor proteins expressed on a range of tumor cell types, and acts to destroy local, as well as metastatic cancer cells through cell lysis and the generation of a specific immune response against the cancer cells. CAVATAK is a naturally occurring, genetically unaltered virus with activity in a range of cancer types, including, but not limited to melanoma, prostate, lung, and bladder cancers. CAVATAK is being evaluated in Phase I and II clinical trials, both as an intratumoural and intravenous agent.

Directors
Last Annual June 30th, 2017
Last Interim December 31st, 2017
Incorporated August 14, 1986
Public Since October 17, 1986
No. of Shareholders: 5,824
No. of Employees: 3
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange Australian Stock Exchange - SEATS
Shares in Issue 240,924,252
Free Float (0.0%)
Eligible for
ISAs
SIPPs
VLA Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for VLA
Upcoming Events for VLA
Frequently Asked Questions for Viralytics
What is the Viralytics share price?

As of 05/06/18, shares in Viralytics are trading at A$1.75, giving the company a market capitalisation of £n/a. This share price information is delayed by 15 minutes.

How has the Viralytics share price performed this year?

Shares in Viralytics are currently trading at A$1.75 and the price has moved by 66.19% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Viralytics price has moved by 27.11% over the past year.

What are the analyst and broker recommendations for Viralytics?

Of the analysts with advisory recommendations for Viralytics, there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for Viralytics is Not available. You can view the full broker recommendation list by unlocking its StockReport.

When will Viralytics next release its financial results?

Viralytics is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2018-12-31
What is the Viralytics dividend yield?

Viralytics does not currently pay a dividend.

Does Viralytics pay a dividend?

Viralytics does not currently pay a dividend.

When does Viralytics next pay dividends?

Viralytics does not currently pay a dividend.

How do I buy Viralytics shares?

To buy shares in Viralytics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Viralytics?

Shares in Viralytics are currently trading at A$1.75, giving the company a market capitalisation of £n/a.

Where are Viralytics shares listed? Where are Viralytics shares listed?

Here are the trading details for Viralytics:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: VLA
What kind of share is Viralytics?

We were not able to load our ranking data for Viralytics

Is there a Viralytics share price forecast 2021?

We were not able to load any forecast data for Viralytics.

How can I tell whether the Viralytics share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Viralytics. Over the past six months, the relative strength of its shares against the market has been 0.153k%. At the current price of A$1.75, shares in Viralytics are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Viralytics PE Ratio?

We were not able to find PE ratio data for Viralytics.

Who are the key directors of Viralytics?

We were unable to find the directors for Viralytics.

Who are the major shareholders of Viralytics?

Here are the top five shareholders of Viralytics based on the size of their shareholding:

Similar to VLA
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.